Response to clozapine in a clinically identifiable subtype of schizophrenia: 22q11.2 deletions mediate side effect risk and dosage.

Butcher NJ, Fung WLA, Fitzpatrick L, Guna A, Andrade D, Lang A, Chow EWC, Bassett AS: British Journal of Psychiatry 206:484-491, 2015 (doi:10.1192/bjp.bp.114.151837)

This research explored how individuals with 22q and schizophrenia respond to the medication clozapine, and how it differs from individuals with schizophrenia who do not have 22q. We found that a lower dose of clozapine and using preventative measures can help lower the risks of side effects for individuals with 22q.